Erika De Boever, DDS MPH PhD

Erika De Boever has over 20 years’ experience in clinical development and project leadership in the pharmaceutical and biotech industry with extensive expertise in AAV and LVV gene therapies for rare and common diseases.

Ms. De Boever has hands-on clinical development, translational medicine and program strategy consulting services for small and large molecules across all stages of development, from pre-IND/CTA to Phase IV. She currently serves on the Scientific Advisory Board for the Center for Dental, Oral and Craniofacial Tissue and Organ Regeneration (C-DOCTOR) and the Michigan-Pittsburgh-Wyss Regenerative Medicine (MPWRM) Resource Center.

During her tenure at GSK, Ms. De Boever was a lead clinical development scientist in development and approval of Strimvelis, the first pediatric gene therapy for the treatment of ADA-SCID, and in the development of Libmeldy for the treatment of metachromatic leukodystrophy (MLD).

Ms. De Boever has a DDS from the University of Ghent (Belgium) and an MPH and PhD from the University of Michigan.